| Authors: |
Hamy AS; Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France.; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France., Abécassis J; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.; INRIA, Université Paris-Saclay, CEA, Palaiseau, France., Driouch K; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France., Darrigues L; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France., Vandenbogaert M; Translational Research Department, Institut Curie Research Center, PSL University, Paris, France.; INSERM U830, Institut Curie, PSL University, Paris, France., Laurent C; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France., Zaccarini F; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France., Sadacca B; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.; INSERM U830, Institut Curie, PSL University, Paris, France., Delomenie M; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France., Laas E; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France., Mariani O; Biological Resource Center, Department of Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Paris, France., Lam T; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France.; Department of Gynecology and Obstetrics, Geneva University Hospitals, Geneva, Switzerland., Grandal B; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France.; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France., Laé M; Biological Resource Center, Department of Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Paris, France.; Department of Pathology, Centre Henri Becquerel, INSERM U1245, UNIROUEN, University of Normandie, Rouen, France., Bieche I; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France.; INSERM U1016, Faculty of Pharmaceutical and Biological Sciences, Université de Paris Cité, Paris, France., Vacher S; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France., Pierga JY; Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France., Brain E; Department of Medical Oncology, Institut Curie, Université Paris Cité, Paris, France., Vallot C; Translational Research Department, Institut Curie Research Center, PSL University, Paris, France.; CNRS UMR3244, Institut Curie, PSL University, Paris, France., Hotton J; Department of Surgical Oncology, Institut Godinot, Reims, France., Richer W; Translational Research Department, Institut Curie Research Center, PSL University, Paris, France.; Translational Immunotherapy Team, INSERM U932, Institut Curie, PSL University, Paris, France., Rocha D; Translational Immunotherapy Team, INSERM U932, Institut Curie, PSL University, Paris, France., Tariq Z; Pharmacogenomics Unit, Department of Genetics, PSL University, Institut Curie, Paris, France., Becette V; Biological Resource Center, Department of Pathology, Department of Diagnostic and Theranostic Medicine, Institut Curie, PSL University, Paris, France., Meseure D; Department of Diagnostic and Theranostic Medicine, Institut Curie, University Paris-Sciences et Lettres, Paris, France., Lesage L; Department of Diagnostic and Theranostic Medicine, Institut Curie, University Paris-Sciences et Lettres, Paris, France., Vincent-Salomon A; Department of Diagnostic and Theranostic Medicine, Institut Curie, University Paris-Sciences et Lettres, Paris, France., Filmann N; German Breast Group, Neu-Isenburg, Germany., Furlanetto J; German Breast Group, Neu-Isenburg, Germany., Loibl S; German Breast Group, Neu-Isenburg, Germany.; Centre for Haematology and Oncology/Bethanien, Frankfurt am Main, Germany., Dumas E; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France., Waterfall JJ; Translational Research Department, Institut Curie Research Center, PSL University, Paris, France. joshua.waterfall@curie.fr.; INSERM U830, Institut Curie, PSL University, Paris, France. joshua.waterfall@curie.fr., Reyal F; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Paris, INSERM, U932 Immunity and Cancer, Institut Curie, Université de Paris, Paris, France. fabien.reyal@curie.fr.; Department of Breast, Gynecological and Reconstructive Surgery, Institut Curie, Université de Paris Cité, Paris, France. fabien.reyal@curie.fr. |
